share_log

賽生藥業:根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 19 04:45
Summary by Moomoo AI
赛生药业控股有限公司於2024年4月19日宣布,公司執行人員潘蓉容根據香港《公司收購及合併守則》規則22,於2024年4月18日透過協議安排進行了一宗涉及230,000份股票期權的交易。該期權交易是根據公司購股權激勵計劃進行,並且是為本身帳戶進行的。期權的行使期限自2024年4月18日起至2030年4月18日,行使價為每股7.8920港元,而期權金額則為0.0000港元。交易完成後,潘蓉容持有的賽生药业股份總數達到4,160,000股。
赛生药业控股有限公司於2024年4月19日宣布,公司執行人員潘蓉容根據香港《公司收購及合併守則》規則22,於2024年4月18日透過協議安排進行了一宗涉及230,000份股票期權的交易。該期權交易是根據公司購股權激勵計劃進行,並且是為本身帳戶進行的。期權的行使期限自2024年4月18日起至2030年4月18日,行使價為每股7.8920港元,而期權金額則為0.0000港元。交易完成後,潘蓉容持有的賽生药业股份總數達到4,160,000股。
SAI SANG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 19 APRIL 2024 THAT ITS EXECUTIVE OFFICER PAN JUNG-YONG PURSUANT TO RULE 22 OF THE HONG KONG CODE OF COMPANIES ON ACQUISITIONS AND MERGERS CONDUCTED A TRANSACTION ON 18 APRIL 2024 INVOLVING 230,000 SHARE OPTIONS. The options trading is carried out under the Company's Share Option Incentive Scheme and is conducted for its own account. The exercise period of the options is from 18 April 2024 to 18 April 2030. The exercise price is HK$7.8920 per share and the option amount is HK$0.0000. Upon completion of the transaction, the total number of shares held by Pan Yong Pharmaceutical reached 4,160,000 shares.
SAI SANG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 19 APRIL 2024 THAT ITS EXECUTIVE OFFICER PAN JUNG-YONG PURSUANT TO RULE 22 OF THE HONG KONG CODE OF COMPANIES ON ACQUISITIONS AND MERGERS CONDUCTED A TRANSACTION ON 18 APRIL 2024 INVOLVING 230,000 SHARE OPTIONS. The options trading is carried out under the Company's Share Option Incentive Scheme and is conducted for its own account. The exercise period of the options is from 18 April 2024 to 18 April 2030. The exercise price is HK$7.8920 per share and the option amount is HK$0.0000. Upon completion of the transaction, the total number of shares held by Pan Yong Pharmaceutical reached 4,160,000 shares.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more